This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
​​​​​​​Content
Go to Explore ContentEventsMaterialsVideosPatient SupportContactEN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

Home

Recommendations

SOGC Recommendations

NACI Recommendations

CIQ Recommendations

About RSV

About RSV

Infants at Risk

Individuals ≥ 60 Years of Age

About ABRYSVO

Reconstitution and Storage

Dosing and Administration

Mechanism of Action

Efficacy and Safety Profiles

Clinical Trials

MATISSE Study Design

MATISSE Data

MATISSE Safety Profile

RENOIR Study Design

RENOIR Data

RENOIR Safety Profile

More

Coverage Information

Patient Profiles

FAQ

Resources

Product MonographSafety Information
Pfizer Respiratory Vaccine Portfolio
Infants are at high risk for severe infection* Infants are at high risk for severe infection*RSV hospitalizations in infants

Hospitalization rates are the highest in infants, especially within the first 2 months of life.1

> 50% of hospitalizations were found to be in the first 3 months of life.2†

> 75% of hospitalizations were found to be in the first 6 months of life.2†

*ABRYSVO is not indicated to prevent RSV-associated hospitalization/death.

ABRYSVO did not have a statistically significant result in the hospitalization endpoint in the maternal/infant indication.

Infants are at increased risk of severe RSV disease during their first RSV season3,4*‡Infants at increased risk include:
  • Infants 6 months and younger 
    • The younger the child, the higher the risk of hospitalization
  • All premature infants (i.e. born at less than 37 wGA)
  • Infants with:
    • Congenital lung disease
    • Cystic fibrosis
    • Congenital heart disease
    • Severe immunodeficiency
    • Severe congenital airway anomalies
    • Neuromuscular disease

RSV: respiratory syncytial virus; wGA: weeks’ gestational age; SOGC: Society of Obstetricians and Gynaecologists of Canada; NACI: National Advisory Committee on Immunization; CIQ: Comité sur l’immunisation du Québec
†A study designed to combine available data from literature and databases to determine the effect of chronologic age on RSV hospitalizations among US preterm and term infants.2
‡During first RSV season.

RSV: respiratory syncytial virus; wGA: weeks’ gestational age; SOGC: Society of Obstetricians and Gynaecologists of Canada; NACI: National Advisory Committee on Immunization; CIQ: Comité sur l’immunisation du Québec
†A study designed to combine available data from literature and databases to determine the effect of chronologic age on RSV hospitalizations among US preterm and term infants.2
‡During first RSV season.References:Government of Canada. Respiratory syncytial virus (RSV): for health professionals. Accessed September 18, 2024. https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv/health-professionals.html. Parikh RC et al. Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States. Infect Dis Ther. 2017;6(4):477–486.Government of Canada. Respiratory syncytial virus (RSV) vaccines: Canadian immunization guide. Accessed August 13, 2024. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html#a2.2.Centers for Disease Control and Prevention (CDC). RSV in infants and young children. Accessed September 10, 2024. https://www.cdc.gov/rsv/infants-young-children/?CDC_AAref_Val=https://www.cdc.gov/rsv/high-risk/infants-young-children.html.About RSV
Recommendations

Learn more about SOGC, NACI, and CIQ recommendations.

About ABRYSVO

Find information about ABRYSVO.

PP-A1G-CAN-0117-EN

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN
Are you a resident of Quebec?